Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Operating Leases (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Operating Leases for 4 consecutive years, with $18.2 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 4.67% to $18.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.2 million through Dec 2025, up 4.67% year-over-year, with the annual reading at $18.2 million for FY2025, 4.67% up from the prior year.
  • Operating Leases hit $18.2 million in Q4 2025 for Taysha Gene Therapies, up from $16.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $20.4 million in Q4 2022 to a low of $16.5 million in Q3 2025.
  • Historically, Operating Leases has averaged $18.3 million across 4 years, with a median of $18.2 million in 2025.
  • Biggest five-year swings in Operating Leases: dropped 8.4% in 2024 and later increased 4.67% in 2025.
  • Year by year, Operating Leases stood at $20.4 million in 2022, then fell by 7.27% to $19.0 million in 2023, then dropped by 8.4% to $17.4 million in 2024, then increased by 4.67% to $18.2 million in 2025.
  • Business Quant data shows Operating Leases for TSHA at $18.2 million in Q4 2025, $16.5 million in Q3 2025, and $16.8 million in Q2 2025.